Humacyte (HUMA) Income from Continuing Operations (2020 - 2026)
Humacyte (HUMA) posted quarterly Income from Continuing Operations of 30841000.0 for Q1 2026, down 20.77% year-over-year from 38923521.52 in Q1 2025, and little changed quarter-over-quarter from 30920000.0 in Q4 2025.
Humacyte (HUMA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Income from Continuing Operations for 7 consecutive years, with 30841000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 20.77% year-over-year to 30841000.0; the TTM figure through Mar 2026 stood at 179218000.0 (down 52.74% YoY), while the FY2025 annual figure was 116800000.0, up 60.16% from the prior year.
- Income from Continuing Operations was little changed at 30841000.0 in Q1 2026 per HUMA's latest filing, from 30920000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 19718000.0 in Q2 2022 and bottomed at 86017000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 30771294.12 across 5 years, with a median of 29336000.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations climbed 23.74% — and 2025, when it tumbled 170.83%.
- Humacyte's Income from Continuing Operations stood at 21025000.0 in 2022, then sank by 42.58% to 29977000.0 in 2023, then gained by 2.14% to 29336000.0 in 2024, then slipped by 5.4% to 30920000.0 in 2025, then climbed by 0.26% to 30841000.0 in 2026.
- Business Quant data shows HUMA's Income from Continuing Operations at 30841000.0 in Q1 2026, 30920000.0 in Q4 2025, and 86017000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | -28.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.93 Mn |
| Mar 31, 2026 | -30.84 Mn |
| Dec 31, 2025 | -30.92 Mn |
| Sep 30, 2025 | -86.02 Mn |
| Jun 30, 2025 | -31.44 Mn |
| Mar 31, 2025 | -25.54 Mn |
| Dec 31, 2024 | -29.34 Mn |
| Sep 30, 2024 | -31.76 Mn |
| Jun 30, 2024 | -30.70 Mn |
| Mar 31, 2024 | -27.39 Mn |
| Dec 31, 2023 | -29.98 Mn |
| Sep 30, 2023 | -24.72 Mn |
| Jun 30, 2023 | -26.96 Mn |
| Mar 31, 2023 | -22.72 Mn |
| Dec 31, 2022 | -21.03 Mn |
| Sep 30, 2022 | -24.25 Mn |
| Jun 30, 2022 | -19.72 Mn |
| Mar 31, 2022 | -29.80 Mn |
| Dec 31, 2021 | -23.01 Mn |
| Sep 30, 2021 | -31.56 Mn |